Prospective Tolerability Assessment of a Probiotic Dietary Supplement

NCT ID: NCT04044144

Last Updated: 2022-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-12

Study Completion Date

2019-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The dietary supplement being investigated is a formula containing a combination of eight probiotic strains. The combination formula was developed to support general gastrointestinal and immune health. Each of the strains in the formula have previously been studied in human subjects, including several clinical populations. However, the present eight strain combination formula has not previously been evaluated in human subjects. This prospective study will evaluate the tolerability of the eight strain formula in healthy adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background \& Significance:

The dietary supplement being investigated is a formula containing a combination of eight probiotic strains. The combination formula was developed to support general gastrointestinal and immune health. Each of the strains in the formula have previously been studied in human subjects, including several clinical populations. However, the present eight strain combination formula has not previously been evaluated in human subjects.

Research Design \& Methods:

This prospective study will evaluate the tolerability of the eight strain formula in healthy adults over a 10-day period. The primary aim of the study is to assess tolerability as determined by the frequency of study participants who withdraw from the study due to adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single Group Assignment
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic Dietary Supplement

Subjects will be asked to take 1 capsule per day of the dietary supplement for a period of 10 days

Group Type EXPERIMENTAL

Probiotic Dietary Supplement

Intervention Type DIETARY_SUPPLEMENT

Dietary supplement containing a combination of 8 probiotic strains

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic Dietary Supplement

Dietary supplement containing a combination of 8 probiotic strains

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Age 21-75 years

Exclusion Criteria

* Currently taking a probiotic, prebiotic, or fiber supplement (or they were taken within 10 days prior to screening)
* Currently taking antibiotic, antiparasitic, or antifungal medications orally or intravenously (or they were taken within 28 days prior to screening)
* Currently taking any supplements or medications impacting gastrointestinal motility
* Active gastrointestinal infection
* Current or previous history of chronic bowel disease
* Current or previous history of liver disease
* Current or previous history of chronic kidney disease
* History of gastrointestinal surgery
* A major medical or surgical event requiring hospitalization within 3 months prior to screening
* Current or previous history of cardiovascular disease
* Current or previous history of pre-Diabetes, diabetes mellitus, or hypoglycemia
* Known infection with human immunodeficiency virus, tuberculosis, hepatitis B or hepatitis C
* Genitourinary bacterial infections within 28 days prior to screening
* Current or previous history of seizure disorder
* Current or previous history of psychiatric illness
* History of alcoholism
* Cancer within the last 5 years
* Smoking or use of nicotine containing products within 28 days prior to screening
* Use of drugs of abuse and recreational drugs/substances within 12 months prior to screening
* Known intolerance or allergy to ingredients in the study supplement
* Women who are lactating, pregnant or planning pregnancy within the next two months
* Currently participating in another interventional research study or participated in another interventional study within 28 days prior to screening
Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National University of Natural Medicine

OTHER

Sponsor Role collaborator

Metagenics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Noelle Patno, PhD

Role: PRINCIPAL_INVESTIGATOR

Metagenics, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Personalized Lifestyle Medicine Center

Gig Harbor, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Ryan JJ, Patno NM. Short-Term Tolerability, Safety, and Gut Microbial Composition Responses to a Multi-Strain Probiotic Supplement: An Open-Label Study in Healthy Adults. Integr Med (Encinitas). 2021 Feb;20(1):24-34.

Reference Type RESULT
PMID: 34393673 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.